<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Impetigo</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Impetigo</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Impetigo</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Larry M Baddour, MD, FIDSA, FAHA</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel J Sexton, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ted Rosen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 13, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Impetigo is a contagious, superficial bacterial infection observed most frequently in children ages two to five years, although older children and adults may also be affected. It may be classified as primary impetigo (direct bacterial invasion of previously normal skin)  (<a class="graphic graphic_picture graphicRef96268 graphicRef96267 graphicRef59762 graphicRef96269 graphicRef96272" href="/z/d/graphic/96268.html" rel="external">picture 1A-E</a>) or secondary impetigo (infection at sites of minor skin trauma such as abrasions, minor trauma, and insect bites, or underlying conditions such as eczema  (<a class="graphic graphic_picture graphicRef96275" href="/z/d/graphic/96275.html" rel="external">picture 2</a>)). Pyoderma and impetigo contagiosa are sometimes used as synonyms for primary impetigo. The occurrence of secondary impetigo is sometimes referred to as "impetiginization."</p><p>The infection usually occurs in warm, humid conditions and is easily spread among individuals in close contact; risk factors include poverty, crowding, poor hygiene, and underlying scabies [<a href="#rid1">1,2</a>]. Carriage of group A <em>Streptococcus </em>(GAS; <em>Streptococcus</em> <em>pyogenes</em>) and <em>Staphylococcus aureus</em> predisposes to subsequent impetigo [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Variants of impetigo include nonbullous impetigo, bullous impetigo, and ecthyma. Systemic symptoms are usually absent. Regional lymphadenitis may occur.</p><p class="headingAnchor" id="H3"><span class="h2">Nonbullous impetigo</span><span class="headingEndMark"> — </span>Nonbullous impetigo is the most common form of impetigo. Lesions begin as papules that progress to vesicles surrounded by erythema. Subsequently they become pustules that enlarge and rapidly break down to form thick, adherent crusts with a characteristic golden appearance; this evolution usually occurs over approximately one week  (<a class="graphic graphic_picture graphicRef96268 graphicRef96267 graphicRef63314 graphicRef75066" href="/z/d/graphic/96268.html" rel="external">picture 1A-B, 1F-G</a>). Lesions usually involve the face and extremities. Multiple lesions may develop but tend to remain well localized.</p><p class="headingAnchor" id="H4"><span class="h2">Bullous impetigo</span><span class="headingEndMark"> — </span>Bullous impetigo is a form of impetigo seen primarily in young children in which the vesicles enlarge to form flaccid bullae with clear yellow fluid, which later becomes darker and more turbid; ruptured bullae leave a thin brown crust  (<a class="graphic graphic_picture graphicRef96269 graphicRef96272 graphicRef97673" href="/z/d/graphic/96269.html" rel="external">picture 1D-E, 1H</a>) [<a href="#rid4">4,5</a>]. Usually there are fewer lesions than in nonbullous impetigo, and the trunk is more frequently affected. Bullous impetigo in an adult with appropriate demographic risk factors should prompt an investigation for previously undiagnosed HIV infection [<a href="#rid6">6</a>].</p><p>Bullous impetigo is due to strains of <em>S. aureus</em> that produce exfoliative toxin A, a toxin that causes loss of cell adhesion in the superficial epidermis by targeting the protein desmoglein 1 [<a href="#rid7">7</a>]. This mechanism is related to the pathophysiology of pemphigus, in which autoantibodies are directed against the same protein [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/83684.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of pemphigus"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Ecthyma</span><span class="headingEndMark"> — </span>Ecthyma is an ulcerative form of impetigo in which the lesions extend through the epidermis and deep into the dermis. They consist of "punched-out" ulcers covered with yellow crust surrounded by raised violaceous margins  (<a class="graphic graphic_picture graphicRef96273 graphicRef96274" href="/z/d/graphic/96273.html" rel="external">picture 3A-B</a>) [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H6"><span class="h1">POSTINFECTIOUS SEQUELAE</span></p><p class="headingAnchor" id="H7"><span class="h2">Poststreptococcal glomerulonephritis</span><span class="headingEndMark"> — </span>Poststreptococcal glomerulonephritis is a potential complication of streptococcal impetigo that occurs after infection. Common clinical findings include edema, hypertension, fever, and hematuria [<a href="#rid10">10,11</a>]. (See  <a class="medical medical_review" href="/z/d/html/6118.html" rel="external">"Poststreptococcal glomerulonephritis"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Rheumatic fever</span><span class="headingEndMark"> — </span>In Australian aboriginal communities, where acute rheumatic fever is hyperendemic, low rates of streptococcal pharyngitis and high rates of impetigo have been observed [<a href="#rid12">12</a>]. Observers have hypothesized that streptococcal skin infections such as impetigo may be protective against pharyngitis but may be followed by sequelae such as acute rheumatic fever. (See  <a class="medical medical_review" href="/z/d/html/3177.html" rel="external">"Acute rheumatic fever: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">MICROBIOLOGY</span><span class="headingEndMark"> — </span>The principal pathogen is <em>S. aureus</em>. Beta-hemolytic streptococci (primarily group A but occasionally other serogroups, such as C and G) account for a minority of cases, either alone or in combination with <em>S. aureus</em> [<a href="#rid13">13-15</a>]. The relative frequency of <em>S. aureus</em> infections has changed with time. It was predominant in the 1940s and 1950s, after which group A <em>Streptococcus</em> (GAS) became more prevalent. Since the 1990s, <em>S. aureus</em> has become more common again [<a href="#rid16">16</a>]. </p><p>Methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) is detected in some cases of impetigo. In a Chinese study that investigated the antimicrobial susceptibility of 984 <em>S. aureus</em> isolates taken from sites of impetigo in children, community-acquired MRSA (CA-MRSA) was identified in 1 percent [<a href="#rid17">17</a>]. Other studies have found higher rates of MRSA in impetigo [<a href="#rid18">18-20</a>]. As an example, a Japanese study of 136 <em>S. aureus</em> isolates from children with impetigo found CA-MRSA in 10 percent [<a href="#rid18">18</a>].</p><p>Bullous impetigo is caused by strains of <em>S. aureus</em> that produce a toxin causing cleavage in the superficial skin layer (see <a class="local">'Bullous impetigo'</a> above). Ecthyma is due to GAS.</p><p>Streptococcal colonization of intact skin precedes inoculation via breaches in the skin; bacteria may be subsequently transferred from the skin to the upper respiratory tract. The GAS virulence factor, M protein, can be encoded by one of five chromosome patterns of <em>emm</em> genes (denoted A through E) [<a href="#rid21">21</a>]. Pharyngeal strains usually have patterns A-C, while nearly all impetigo strains have patterns D or E [<a href="#rid22">22</a>]. The impetigo strains' patterns are rarely observed among invasive clinical isolates [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H10"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of impetigo often can be made on the basis of clinical manifestations. The key clinical findings of nonbullous impetigo, bullous impetigo, and ecthyma include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonbullous impetigo </strong>–<strong> </strong>Papules, vesicles, and pustules that rapidly break down to form golden adherent crusts; often located on the face or extremities  (<a class="graphic graphic_picture graphicRef96268 graphicRef96267 graphicRef63314 graphicRef75066" href="/z/d/graphic/96268.html" rel="external">picture 1A-B, 1F-G</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bullous impetigo </strong>– Flaccid, fluid-filled bullae that rupture and leave a thin brown crust; often located on the trunk  (<a class="graphic graphic_picture graphicRef96269 graphicRef96272" href="/z/d/graphic/96269.html" rel="external">picture 1D-E</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ecthyma </strong>–<strong> </strong>"Punched-out" ulcers with overlying crusts and raised violaceous borders  (<a class="graphic graphic_picture graphicRef96273 graphicRef96274" href="/z/d/graphic/96273.html" rel="external">picture 3A-B</a>)</p><p></p><p>A Gram stain and culture of pus or exudate is recommended to identify whether <em>S. aureus</em> and/or a beta-hemolytic <em>Streptococcus</em> is the cause. However, treatment may be initiated without these studies in patients with typical clinical presentations [<a href="#rid24">24</a>].</p><p>Serologic testing for streptococcal antibodies is not useful for the diagnosis of impetigo; the anti-streptolysin O (ASO) response is weak, likely because skin lipids suppress streptolysin O response [<a href="#rid25">25-27</a>]. Anti-deoxyribonuclease B (anti-DNase B) and antihyaluronidase (AHT) response are more reliable than the ASO response following group A <em>Streptococcus </em>(GAS) skin infections. However, serologic testing can be helpful in the setting of impetigo with subsequent presumed poststreptococcal glomerulonephritis. (See  <a class="medical medical_review" href="/z/d/html/6118.html" rel="external">"Poststreptococcal glomerulonephritis", section on 'Serology'</a>.)</p><p class="headingAnchor" id="H1111243"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of impetigo differs based upon the clinical presentation. Gram stain and culture are useful for confirming the etiologic diagnosis (see <a class="local">'Microbiology'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonbullous impetigo </strong>– Skin conditions that may share features with nonbullous impetigo include a variety of inflammatory conditions that may present with localized areas of inflammation. Examples include contact dermatitis  (<a class="graphic graphic_picture graphicRef72864 graphicRef51066" href="/z/d/graphic/72864.html" rel="external">picture 4A-B</a>), tinea infection  (<a class="graphic graphic_picture graphicRef87000 graphicRef86999" href="/z/d/graphic/87000.html" rel="external">picture 5A-B</a>), and eczema herpeticum and other herpes simplex virus infections  (<a class="graphic graphic_picture graphicRef121502 graphicRef121503" href="/z/d/graphic/121502.html" rel="external">picture 6A-B</a>). Recognition of the characteristic golden crust should raise suspicion for impetigo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bullous impetigo </strong>– Bullous impetigo should be differentiated from other blistering skin conditions. Examples include autoimmune blistering diseases  (<a class="graphic graphic_table graphicRef76641" href="/z/d/graphic/76641.html" rel="external">table 1</a>), acute contact dermatitis  (<a class="graphic graphic_picture graphicRef74631" href="/z/d/graphic/74631.html" rel="external">picture 7</a>), bullous drug eruptions, burns, bullous insect bite reactions  (<a class="graphic graphic_picture graphicRef60230" href="/z/d/graphic/60230.html" rel="external">picture 8</a>), varicella  (<a class="graphic graphic_picture graphicRef94664" href="/z/d/graphic/94664.html" rel="external">picture 9</a>), and subcorneal pustular dermatosis  (<a class="graphic graphic_picture graphicRef52552" href="/z/d/graphic/52552.html" rel="external">picture 10</a>). The progression from bullae to erosions with peripheral crust is characteristic of bullous impetigo. (See  <a class="medical medical_review" href="/z/d/html/13684.html" rel="external">"Approach to the patient with cutaneous blisters"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ecthyma </strong>– The differential diagnosis of ecthyma often includes other conditions that may cause localized ulcers, such as mycobacterial or deep fungal infections  (<a class="graphic graphic_picture graphicRef68569 graphicRef67553" href="/z/d/graphic/68569.html" rel="external">picture 11A-B</a>) or pyoderma gangrenosum  (<a class="graphic graphic_picture graphicRef83692 graphicRef72260" href="/z/d/graphic/83692.html" rel="external">picture 12A-B</a>). Ecthyma can be confused with ecthyma gangrenosum, a potentially life-threatening skin condition that occurs in patients with pseudomonal bacteremia. In ecthyma gangrenosum, painless erythematous or purpuric macules rapidly evolve into hemorrhagic vesicles or bullae that subsequently rupture to leave an ulcer with necrotic black eschar  (<a class="graphic graphic_picture graphicRef53544 graphicRef97674" href="/z/d/graphic/53544.html" rel="external">picture 13A-B</a>). Unlike ecthyma, patients with ecthyma gangrenosum are usually systemically ill. (See  <a class="medical medical_review" href="/z/d/html/7643.html" rel="external">"Pseudomonas aeruginosa skin and soft tissue infections", section on 'Ecthyma Gangrenosum'</a>.)</p><p></p><p class="headingAnchor" id="H11"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Treatment of impetigo is important for reducing spread of infection, hastening the resolution of discomfort, and improving cosmetic appearance [<a href="#rid28">28</a>]. Bullous and nonbullous impetigo can be treated with either topical or oral therapy. Topical therapy is used for patients with limited skin involvement, whereas oral therapy is recommended for patients with numerous lesions [<a href="#rid24">24</a>]. Unlike impetigo, ecthyma should always be treated with oral therapy [<a href="#rid24">24</a>]. In healthcare settings, contact precautions to avoid spread of impetigo are indicated until 24 hours after the start of antibiotic therapy [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H1110234"><span class="h2">Limited impetigo</span><span class="headingEndMark"> — </span>Topical therapy for impetigo should be administered if there are a limited number of lesions.</p><p class="headingAnchor" id="H1110810"><span class="h3">Topical therapy</span><span class="headingEndMark"> — </span>Benefits of topical therapy include fewer side effects and lower risk for contributing to bacterial resistance compared with oral therapy [<a href="#rid28">28</a>]. <a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">Mupirocin</a> and <a class="drug drug_general" data-topicid="10271" href="/z/d/drug information/10271.html" rel="external">retapamulin</a> are first-line treatments [<a href="#rid24">24</a>]. Mupirocin is applied three times daily and retapamulin is applied twice daily. The recommended length of treatment is five days [<a href="#rid24">24</a>]. </p><p>Topical <a class="drug drug_general" data-topicid="8648" href="/z/d/drug information/8648.html" rel="external">fusidic acid</a> can be effective for impetigo; however, evidence for increasing resistance of <em>S. aureus</em> to fusidic acid in locations where topical fusidic acid use is common has made it a less favorable option for therapy [<a href="#rid30">30</a>]. Fusidic acid is not available in the United States.</p><p>Although the components of over-the-counter triple antibiotic ointments (consisting of <a class="drug drug_general" data-topicid="9058" href="/z/d/drug information/9058.html" rel="external">bacitracin-neomycin-polymyxin B</a>) have some activity against the organisms causing impetigo, they may not be as effective for treatment [<a href="#rid31">31</a>]. Therefore, treatment of impetigo with these agents is not recommended. <a class="drug drug_general" data-topicid="9052" href="/z/d/drug information/9052.html" rel="external">Bacitracin</a> and <a class="drug drug_general" data-topicid="9686" href="/z/d/drug information/9686.html" rel="external">neomycin</a> can also cause contact dermatitis. In rare cases, bacitracin has been associated with allergic anaphylactoid reactions [<a href="#rid32">32</a>].</p><p><a class="drug drug_general" data-topicid="116158" href="/z/d/drug information/116158.html" rel="external">Ozenoxacin</a>, a topical quinolone, was approved by the US Food and Drug Administration (FDA) in 2017 for the treatment of impetigo [<a href="#rid33">33,34</a>]. However, additional study is necessary to clarify its benefits, risks, and likelihood for promoting bacterial drug resistance relative to standard therapy prior to a recommendation for use as a primary therapy for impetigo.</p><p class="headingAnchor" id="H1110241"><span class="h2">Extensive impetigo and ecthyma</span><span class="headingEndMark"> — </span>Oral therapy should be administered to patients with numerous impetigo lesions or ecthyma.</p><p class="headingAnchor" id="H13"><span class="h3">Systemic antibiotics</span><span class="headingEndMark"> — </span>Unless cultures reveal only beta-hemolytic streptococci (usually group A <em>Streptococcus </em>[GAS])<em>,</em> the oral antibiotic prescribed for impetigo and ecthyma should be effective for the treatment of both <em>S. aureus </em>and streptococcal infections  (<a class="graphic graphic_table graphicRef96693" href="/z/d/graphic/96693.html" rel="external">table 2</a>) (see <a class="local">'Streptococcal impetigo'</a> below). <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">Cephalexin</a> and <a class="drug drug_general" data-topicid="9349" href="/z/d/drug information/9349.html" rel="external">dicloxacillin</a> are appropriate treatments because <em>S. aureus</em> isolates from impetigo and ecthyma are usually susceptible to methicillin [<a href="#rid24">24</a>]. Although <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> and <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> can also treat impetigo, some strains of<em> S. aureus</em> and GAS<em> </em>may be resistant to these therapies [<a href="#rid24">24</a>]. Therapeutic options for impetigo are provided in a table  (<a class="graphic graphic_table graphicRef96693" href="/z/d/graphic/96693.html" rel="external">table 2</a>). A seven-day course of oral antibiotic treatment is recommended [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H1110310"><span class="h2">Special cases</span><span class="headingEndMark"> — </span>Certain scenarios warrant adjustments in the approach to treatment. </p><p class="headingAnchor" id="H1110261"><span class="h3">Streptococcal impetigo</span><span class="headingEndMark"> — </span>If only beta-hemolytic streptococci are detected in extensive impetigo or ecthyma, oral penicillin is the preferred therapy [<a href="#rid24">24</a>]. Limited streptococcal impetigo can be treated with topical therapy. (See <a class="local">'Limited impetigo'</a> above.)</p><p>Although the efficacy of <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> for streptococcal infections has been perceived as uncertain, the findings of an open-label, assessor-blinded randomized trial performed in 508 children in remote Australia suggest that oral trimethoprim-sulfamethoxazole is an effective alternative to injectable penicillin for the treatment of impetigo in which streptococcal infection is present [<a href="#rid35">35</a>]. In the trial, three- or five-day courses of oral trimethoprim-sulfamethoxazole and a single injection of benzathine benzylpenicillin were similarly effective for improving or healing impetigo within seven days<em>. </em>Ninety percent of children in the trial were culture-positive for <em>S. pyogenes</em> with or without concomitant <em>S. aureus </em>infection. Although not a first-line treatment for <strong>non</strong>-methicillin-resistant <em>S. aureus </em>impetigo, a short course of oral trimethoprim-sulfamethoxazole may represent an inexpensive oral alternative for staphylococcal and streptococcal impetigo in resource-limited settings.</p><p class="headingAnchor" id="H1110274"><span class="h3">MRSA impetigo</span><span class="headingEndMark"> — </span>Patients with suspected or confirmed methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) infections can be treated with <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>, or <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, provided the causative isolate is susceptible to the selected agent  (<a class="graphic graphic_table graphicRef96693" href="/z/d/graphic/96693.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/3176.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of skin and soft tissue infections"</a>.) </p><p>Regarding <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, although tetracyclines can cause permanent tooth discoloration in children younger than eight years, doxycycline binds less to calcium than do other tetracyclines. Therefore, short courses of doxycycline (21 days or less) can be given to children who fall within this age group [<a href="#rid36">36</a>]. Also, it is important for patients to avoid excess sun exposure due to photosensitivity associated with doxycycline.</p><p>Fluoroquinolones should <strong>not</strong> be used to treat impetigo, as MRSA resistance to this class is widespread and resistance can develop on therapy. (See  <a class="medical medical_review" href="/z/d/html/3176.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of skin and soft tissue infections"</a>.)</p><p class="headingAnchor" id="H1110332"><span class="h3">Impetigo outbreaks</span><span class="headingEndMark"> — </span>Oral therapy rather than topical therapy is recommended in outbreaks, including those complicated by poststreptococcal glomerulonephritis  (<a class="graphic graphic_table graphicRef96693" href="/z/d/graphic/96693.html" rel="external">table 2</a>) [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H3784824333"><span class="h3">Coinfection with scabies</span><span class="headingEndMark"> — </span>Treatment of scabies in patients with impetigo is important for optimizing the response of impetigo to antibiotic therapy and reducing the prevalence of impetigo in areas of high scabies prevalence [<a href="#rid37">37-41</a>]. (See  <a class="medical medical_review" href="/z/d/html/114369.html" rel="external">"Scabies: Management", section on 'Endemic scabies'</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Follow-up</span><span class="headingEndMark"> — </span>Crusted lesions can be washed gently. Handwashing is important for reducing spread among children, and other preventive measures employed in reducing the spread of staphylococci may also be helpful [<a href="#rid42">42,43</a>]. (See  <a class="medical medical_review" href="/z/d/html/4048.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Prevention and control"</a>.)</p><p>Improvement in impetigo should be noted within a single course of appropriate antibiotic treatment. The possibility of resistant pathogens or an incorrect diagnosis should be considered when lesions fail to respond to antibiotic therapy. (See <a class="local">'Differential diagnosis'</a> above.)</p><p class="headingAnchor" id="H22250835"><span class="h2">Return to school</span><span class="headingEndMark"> — </span>Children can return to school 24 hours after beginning an effective antimicrobial therapy. Draining lesions should be kept covered.</p><p class="headingAnchor" id="H3068831035"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110086.html" rel="external">"Society guideline links: Skin and soft tissue infections"</a>.)</p><p class="headingAnchor" id="H371024292"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15458.html" rel="external">"Patient education: Impetigo (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/7630.html" rel="external">"Patient education: Impetigo (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– Impetigo is a contagious, superficial bacterial infection that typically involves the face and extremities with lesions that progress from papules to vesicles, pustules, and crusts  (<a class="graphic graphic_picture graphicRef96268 graphicRef96267" href="/z/d/graphic/96268.html" rel="external">picture 1A-B</a>). Less common manifestations include bullous impetigo and ecthyma  (<a class="graphic graphic_picture graphicRef59762 graphicRef96269 graphicRef96272 graphicRef96274 graphicRef96273" href="/z/d/graphic/59762.html" rel="external">picture 1C-E, 3A-B</a>). Impetigo may be complicated by poststreptococcal glomerulonephritis or rheumatic fever. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiology </strong>– The most common pathogen is <em>Staphylococcus aureus</em>. In contrast to skin abscess, community-acquired methicillin-resistant <em>Staphylococcus aureus</em> (CA-MRSA) is an uncommon cause of impetigo. Beta-hemolytic streptococci (primarily group A but occasionally other serogroups, such as C and G) cause a minority of cases, either alone or in combination with <em>S. aureus</em>. (See <a class="local">'Microbiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with limited lesions </strong>– For management of impetigo with a small number of lesions, we recommend treatment with topical therapy rather than oral therapy (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). </p><p></p><p class="bulletIndent2">Topical <a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">mupirocin</a> and topical <a class="drug drug_general" data-topicid="10271" href="/z/d/drug information/10271.html" rel="external">retapamulin</a> are options for topical therapy. Mupirocin is applied three times daily and retapamulin is applied twice daily. The recommended duration of treatment for these medications is five days. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with numerous lesions </strong>– For patients with numerous impetigo lesions, we recommend treatment with oral antibiotic therapy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). </p><p></p><p class="bulletIndent2">The antibiotic selected should be effective for the treatment of bo<em>th S. aureus</em> and streptococcal infections; <a class="drug drug_general" data-topicid="9349" href="/z/d/drug information/9349.html" rel="external">dicloxacillin</a> and <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">cephalexin</a> are appropriate treatments  (<a class="graphic graphic_table graphicRef96693" href="/z/d/graphic/96693.html" rel="external">table 2</a>). Oral antibiotic therapy should be given for seven days. In the setting of suspected CA-MRSA, appropriate choices include <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> or <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>; <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> can be also used  (<a class="graphic graphic_table graphicRef96693" href="/z/d/graphic/96693.html" rel="external">table 2</a>). (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention </strong>– Handwashing is important for reducing spread among children, and other preventive measures employed in reducing the spread of staphylococci may also be helpful. (See  <a class="medical medical_review" href="/z/d/html/4048.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Prevention and control"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bowen AC, Mahé A, Hay RJ, et al. The Global Epidemiology of Impetigo: A Systematic Review of the Population Prevalence of Impetigo and Pyoderma. PLoS One 2015; 10:e0136789.</a></li><li><a class="nounderline abstract_t">Romani L, Steer AC, Whitfeld MJ, Kaldor JM. Prevalence of scabies and impetigo worldwide: a systematic review. Lancet Infect Dis 2015; 15:960.</a></li><li><a class="nounderline abstract_t">Dajani AS, Ferrieri P, Wannamaker LW. Natural history of impetigo. II. Etiologic agents and bacterial interactions. J Clin Invest 1972; 51:2863.</a></li><li><a class="nounderline abstract_t">Edlich RF, Winters KL, Britt LD, Long WB 3rd. Bacterial diseases of the skin. J Long Term Eff Med Implants 2005; 15:499.</a></li><li><a class="nounderline abstract_t">Hirschmann JV. Impetigo: etiology and therapy. Curr Clin Top Infect Dis 2002; 22:42.</a></li><li><a class="nounderline abstract_t">Donovan B, Rohrsheim R, Bassett I, Mulhall BP. Bullous impetigo in homosexual men--a risk marker for HIV-1 infection? Genitourin Med 1992; 68:159.</a></li><li><a class="nounderline abstract_t">Amagai M, Matsuyoshi N, Wang ZH, et al. Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. Nat Med 2000; 6:1275.</a></li><li><a class="nounderline abstract_t">Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N Engl J Med 2006; 355:1800.</a></li><li><a class="nounderline abstract_t">Hewitt WD, Farrar WE. Bacteremia and ecthyma caused by Streptococcus pyogenes in a patient with acquired immunodeficiency syndrome. Am J Med Sci 1988; 295:52.</a></li><li><a class="nounderline abstract_t">Ilyas M, Tolaymat A. Changing epidemiology of acute post-streptococcal glomerulonephritis in Northeast Florida: a comparative study. Pediatr Nephrol 2008; 23:1101.</a></li><li><a class="nounderline abstract_t">Becquet O, Pasche J, Gatti H, et al. Acute post-streptococcal glomerulonephritis in children of French Polynesia: a 3-year retrospective study. Pediatr Nephrol 2010; 25:275.</a></li><li><a class="nounderline abstract_t">McDonald MI, Towers RJ, Andrews RM, et al. Low rates of streptococcal pharyngitis and high rates of pyoderma in Australian aboriginal communities where acute rheumatic fever is hyperendemic. Clin Infect Dis 2006; 43:683.</a></li><li><a class="nounderline abstract_t">Darmstadt GL, Lane AT. Impetigo: an overview. Pediatr Dermatol 1994; 11:293.</a></li><li><a class="nounderline abstract_t">Demidovich CW, Wittler RR, Ruff ME, et al. Impetigo. Current etiology and comparison of penicillin, erythromycin, and cephalexin therapies. Am J Dis Child 1990; 144:1313.</a></li><li><a class="nounderline abstract_t">Baddour LM. Primary skin infections in primary care: An update. Infect Med 1993; 10:42.</a></li><li><a class="nounderline abstract_t">Dagan R. Impetigo in childhood: changing epidemiology and new treatments. Pediatr Ann 1993; 22:235.</a></li><li><a class="nounderline abstract_t">Liu Y, Kong F, Zhang X, et al. Antimicrobial susceptibility of Staphylococcus aureus isolated from children with impetigo in China from 2003 to 2007 shows community-associated methicillin-resistant Staphylococcus aureus to be uncommon and heterogeneous. Br J Dermatol 2009; 161:1347.</a></li><li><a class="nounderline abstract_t">Kikuta H, Shibata M, Nakata S, et al. Predominant Dissemination of PVL-Negative CC89 MRSA with SCCmec Type II in Children with Impetigo in Japan. Int J Pediatr 2011; 2011:143872.</a></li><li><a class="nounderline abstract_t">Shi D, Higuchi W, Takano T, et al. Bullous impetigo in children infected with methicillin-resistant Staphylococcus aureus alone or in combination with methicillin-susceptible S. aureus: analysis of genetic characteristics, including assessment of exfoliative toxin gene carriage. J Clin Microbiol 2011; 49:1972.</a></li><li><a class="nounderline abstract_t">Jenney A, Holt D, Ritika R, et al. The clinical and molecular epidemiology of Staphylococcus aureus infections in Fiji. BMC Infect Dis 2014; 14:160.</a></li><li><a class="nounderline abstract_t">Wasserzug O, Valinsky L, Klement E, et al. A cluster of ecthyma outbreaks caused by a single clone of invasive and highly infective Streptococcus pyogenes. Clin Infect Dis 2009; 48:1213.</a></li><li><a class="nounderline abstract_t">Bessen DE, Sotir CM, Readdy TL, Hollingshead SK. Genetic correlates of throat and skin isolates of group A streptococci. J Infect Dis 1996; 173:896.</a></li><li><a class="nounderline abstract_t">Fiorentino TR, Beall B, Mshar P, Bessen DE. A genetic-based evaluation of the principal tissue reservoir for group A streptococci isolated from normally sterile sites. J Infect Dis 1997; 176:177.</a></li><li><a class="nounderline abstract_t">Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis 2014; 59:147.</a></li><li><a class="nounderline abstract_t">Kaplan EL, Anthony BF, Chapman SS, et al. The influence of the site of infection on the immune response to group A streptococci. J Clin Invest 1970; 49:1405.</a></li><li><a class="nounderline abstract_t">Bisno AL, Nelson KE, Waytz P, Brunt J. Factors influencing serum antibody responses in streptococcal pyoderma. J Lab Clin Med 1973; 81:410.</a></li><li><a class="nounderline abstract_t">Kaplan EL, Wannamaker LW. Suppression of the antistreptolysin O response by cholesterol and by lipid extracts of rabbit skin. J Exp Med 1976; 144:754.</a></li><li><a class="nounderline abstract_t">Koning S, van der Sande R, Verhagen AP, et al. Interventions for impetigo. Cochrane Database Syst Rev 2012; 1:CD003261.</a></li><li class="breakAll">http://www.cdc.gov/hicpac/2007IP/2007ip_appendA.html (Accessed on February 12, 2015).</li><li><a class="nounderline abstract_t">Williamson DA, Monecke S, Heffernan H, et al. High usage of topical fusidic acid and rapid clonal expansion of fusidic acid-resistant Staphylococcus aureus: a cautionary tale. Clin Infect Dis 2014; 59:1451.</a></li><li><a class="nounderline abstract_t">Bass JW, Chan DS, Creamer KM, et al. Comparison of oral cephalexin, topical mupirocin and topical bacitracin for treatment of impetigo. Pediatr Infect Dis J 1997; 16:708.</a></li><li><a class="nounderline abstract_t">Cronin H, Mowad C. Anaphylactic reaction to bacitracin ointment. Cutis 2009; 83:127.</a></li><li><a class="nounderline abstract_t">Rosen T, Albareda N, Rosenberg N, et al. Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial. JAMA Dermatol 2018; 154:806.</a></li><li><a class="nounderline abstract_t">Gropper S, Albareda N, Chelius K, et al. Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial. Future Microbiol 2014; 9:1013.</a></li><li><a class="nounderline abstract_t">van der Wouden JC, Koning S. Treatment of impetigo in resource-limited settings. Lancet 2014; 384:2090.</a></li><li class="breakAll">American Academy of Pediatrics. Antimicrobial agents and related therapy. In: Red Book: 2018 Report of the Committee on Infectious Diseases, 31st ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Itasaca, IL 2018. p.903.</li><li><a class="nounderline abstract_t">Romani L, Whitfeld MJ, Koroivueta J, et al. Mass Drug Administration for Scabies Control in a Population with Endemic Disease. N Engl J Med 2015; 373:2305.</a></li><li><a class="nounderline abstract_t">Tasani M, Tong SY, Andrews RM, et al. The Importance of Scabies Coinfection in the Treatment Considerations for Impetigo. Pediatr Infect Dis J 2016; 35:374.</a></li><li><a class="nounderline abstract_t">Marks M, Toloka H, Baker C, et al. Randomized Trial of Community Treatment With Azithromycin and Ivermectin Mass Drug Administration for Control of Scabies and Impetigo. Clin Infect Dis 2019; 68:927.</a></li><li><a class="nounderline abstract_t">Romani L, Marks M, Sokana O, et al. Efficacy of mass drug administration with ivermectin for control of scabies and impetigo, with coadministration of azithromycin: a single-arm community intervention trial. Lancet Infect Dis 2019; 19:510.</a></li><li><a class="nounderline abstract_t">Marks M, Romani L, Sokana O, et al. Prevalence of Scabies and Impetigo 3 Years After Mass Drug Administration With Ivermectin and Azithromycin. Clin Infect Dis 2020; 70:1591.</a></li><li><a class="nounderline abstract_t">Luby SP, Agboatwalla M, Feikin DR, et al. Effect of handwashing on child health: a randomised controlled trial. Lancet 2005; 366:225.</a></li><li><a class="nounderline abstract_t">Kowalski TJ, Berbari EF, Osmon DR. Epidemiology, treatment, and prevention of community-acquired methicillin-resistant Staphylococcus aureus infections. Mayo Clin Proc 2005; 80:1201.</a></li></ol></div><div id="topicVersionRevision">Topic 7655 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26317533" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The Global Epidemiology of Impetigo: A Systematic Review of the Population Prevalence of Impetigo and Pyoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26088526" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevalence of scabies and impetigo worldwide: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4263498" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Natural history of impetigo. II. Etiologic agents and bacterial interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16218899" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Bacterial diseases of the skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12520646" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Impetigo: etiology and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1607190" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Bullous impetigo in homosexual men--a risk marker for HIV-1 infection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11062541" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17065642" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3276190" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Bacteremia and ecthyma caused by Streptococcus pyogenes in a patient with acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18373105" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Changing epidemiology of acute post-streptococcal glomerulonephritis in Northeast Florida: a comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19876655" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Acute post-streptococcal glomerulonephritis in children of French Polynesia: a 3-year retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16912939" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Low rates of streptococcal pharyngitis and high rates of pyoderma in Australian aboriginal communities where acute rheumatic fever is hyperendemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7899177" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Impetigo: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2244610" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Impetigo. Current etiology and comparison of penicillin, erythromycin, and cephalexin therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Primary skin infections in primary care: An update</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8510990" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Impetigo in childhood: changing epidemiology and new treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19754868" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Antimicrobial susceptibility of Staphylococcus aureus isolated from children with impetigo in China from 2003 to 2007 shows community-associated methicillin-resistant Staphylococcus aureus to be uncommon and heterogeneous.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22187567" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Predominant Dissemination of PVL-Negative CC89 MRSA with SCCmec Type II in Children with Impetigo in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21430094" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Bullous impetigo in children infected with methicillin-resistant Staphylococcus aureus alone or in combination with methicillin-susceptible S. aureus: analysis of genetic characteristics, including assessment of exfoliative toxin gene carriage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24655406" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The clinical and molecular epidemiology of Staphylococcus aureus infections in Fiji.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19331587" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A cluster of ecthyma outbreaks caused by a single clone of invasive and highly infective Streptococcus pyogenes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8603968" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Genetic correlates of throat and skin isolates of group A streptococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9207364" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A genetic-based evaluation of the principal tissue reservoir for group A streptococci isolated from normally sterile sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24947530" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5432372" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The influence of the site of infection on the immune response to group A streptococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4686957" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Factors influencing serum antibody responses in streptococcal pyoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/182898" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Suppression of the antistreptolysin O response by cholesterol and by lipid extracts of rabbit skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22258953" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Interventions for impetigo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22258953" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Interventions for impetigo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25139961" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : High usage of topical fusidic acid and rapid clonal expansion of fusidic acid-resistant Staphylococcus aureus: a cautionary tale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9239775" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Comparison of oral cephalexin, topical mupirocin and topical bacitracin for treatment of impetigo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19363904" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Anaphylactic reaction to bacitracin ointment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29898217" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25340832" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25172375" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Treatment of impetigo in resource-limited settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25172375" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Treatment of impetigo in resource-limited settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26650152" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Mass Drug Administration for Scabies Control in a Population with Endemic Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26599569" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The Importance of Scabies Coinfection in the Treatment Considerations for Impetigo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29985978" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Randomized Trial of Community Treatment With Azithromycin and Ivermectin Mass Drug Administration for Control of Scabies and Impetigo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30956111" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Efficacy of mass drug administration with ivermectin for control of scabies and impetigo, with coadministration of azithromycin: a single-arm community intervention trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31131410" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Prevalence of Scabies and Impetigo 3 Years After Mass Drug Administration With Ivermectin and Azithromycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16023513" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effect of handwashing on child health: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16178500" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Epidemiology, treatment, and prevention of community-acquired methicillin-resistant Staphylococcus aureus infections.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
